Cardiometabolic Effects of a New Class of Antidiabetic Agents.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Clinical Therapeutics

• Publication date

  2015-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.clinthera.2015.02.016PMID 25754876
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Characteristics and short-term outcomes of patients with type 2 diabetes mellitus treated with canagliflozin in a real-world setting

  2015cited by this paper
• A safety evaluation of canagliflozin: a first-in-class treatment for type 2 diabetes

  2014cited by this paper
• SGLT2 inhibitors: New medicines for addressing unmet needs in type 2 diabetes.

  2014cited by this paper
• Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years

  2014cited by this paper
• Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension

  2014cited by this paper
• Follow-up of blood-pressure lowering and glucose control in type 2 diabetes.

  2014cited by this paper
• Sodium glucose transporter protein 2 inhibitors: focusing on the kidney to treat type 2 diabetes

  2014cited by this paper
• Dipeptidyl peptidase‐4 inhibitors and cardiovascular safety

  2014cited by this paper
• Effect of Canagliflozin on Blood Pressure and Adverse Events Related to Osmotic Diuresis and Reduced Intravascular Volume in Patients With Type 2 Diabetes Mellitus

  2014cited by this paper
• HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin

  2014cited by this paper
• HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea

  2014cited by this paper
• Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial

  2014cited by this paper
• Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies

  2014cited by this paper
• DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study

  2014cited by this paper
• Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participants.

  2014cited by this paper
• Safety Profile of Dapagliflozin for Type 2 Diabetes: Pooled Analysis of Clinical Studies for Overall Safety and Rare Events

  2014cited by this paper
• Head‐to‐head comparison of dipeptidyl peptidase‐IV inhibitors and sulfonylureas – a meta‐analysis from randomized clinical trials

  2014cited by this paper
• Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials.

  2014cited by this paper
• Modeling effects of SGLT‐2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes

  2014cited by this paper
• Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials.

  2014cited by this paper
• Pancreatic safety of incretin-based drugs--FDA and EMA assessment.

  2014cited by this paper
• Safety and Efficacy of Dulaglutide, a Once Weekly GLP-1 Receptor Agonist, for the Management of Type 2 Diabetes

  2014cited by this paper
• Albiglutide

  2014cited by this paper
• Dipeptidyl-peptidase-4 Inhibitors and Heart Failure: Class Effect, Substance-Specific Effect, or Chance Effect?

  2014cited by this paper
• Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study.

  2014cited by this paper
• The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus

  2014cited by this paper
• Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial

  2013cited by this paper
• Empagliflozin as Add On to Basal Insulin for 78 Weeks Improves Glycemic Control with Weight Loss in Insulin-Treated Type 2 Diabetes (T2DM)

  2013cited by this paper
• Rationale and Design of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)

  2013cited by this paper
• Alogliptin after acute coronary syndrome in patients with type 2 diabetes.

  2013cited by this paper
• Urinary tract infections in patients with diabetes treated with dapagliflozin.

  2013cited by this paper
• Blood pressure‐lowering effects of GLP‐1 receptor agonists exenatide and liraglutide: a meta‐analysis of clinical trials

  2013cited by this paper
• Standards of Medical Care in Diabetes—2014

  2013cited by this paper
• A novel model-based meta-analysis to indirectly estimate the comparative efficacy of two medications: an example using DPP-4 inhibitors, sitagliptin and linagliptin, in treatment of type 2 diabetes mellitus

  2013cited by this paper
• Dipeptidyl Peptidase‐4 Inhibitors Attenuate Endothelial Function as Evaluated by Flow‐Mediated Vasodilatation in Type 2 Diabetic Patients

  2013cited by this paper
• Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.

  2013cited by this paper
• Exenatide improves endothelial function assessed by flow mediated dilation technique in subjects with type 2 diabetes: Results from an observational research

  2013cited by this paper
• Lixisenatide as add-on therapy to basal insulin

  2013cited by this paper
• A Glucagon-Like Peptide-1 Analog Reverses the Molecular Pathology and Cardiac Dysfunction of a Mouse Model of Obesity

  2013cited by this paper
• Dipeptidyl peptidase‐4 inhibitors and cardiovascular risk: a meta‐analysis of randomized clinical trials

  2013cited by this paper
• Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes

  2013cited by this paper
• Cardiovascular safety of the dipetidyl peptidase‐4 inhibitor alogliptin in type 2 diabetes mellitus

  2013cited by this paper
• Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial.

  2013cited by this paper
• Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin

  2013cited by this paper
• Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis

  2013cited by this paper
• Genital Mycotic Infections in Patients With Diabetes

  2013cited by this paper
• Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis

  2012cited by this paper
• Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes: Meta-Analysis

  2012cited by this paper
• Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus.

  2012cited by this paper
• Case report of acute necrotizing pancreatitis associated with combination treatment of sitagliptin and exenatide.

  2012cited by this paper
• Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study

  2012cited by this paper
• Exenatide Reduces Final Infarct Size in Patients With ST-Segment–Elevation Myocardial Infarction and Short-Duration of Ischemia

  2012cited by this paper
• Dapagliflozin monotherapy in drug‐naïve patients with diabetes: a randomized‐controlled trial of low‐dose range

  2012cited by this paper
• Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme

  2012cited by this paper
• Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta‐analysis of the liraglutide clinical trial programme

  2012cited by this paper
• Glucagon like peptide-1 receptor expression in the human thyroid gland.

  2012cited by this paper
• Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers

  2012cited by this paper
• Efficacy and Safety of Long-Acting Glucagon-Like Peptide-1 Receptor Agonists Compared with Exenatide Twice Daily and Sitagliptin in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis

  2011cited by this paper
• Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretins

  2011cited by this paper
• Dipeptidyl peptidase‐4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta‐analysis of randomized controlled trials

  2011cited by this paper
• DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.

  2011cited by this paper
• Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes

  2011cited by this paper
• The DPP-4 inhibitor linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses.

  2011cited by this paper
• Liraglutide – overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes

  2011cited by this paper
• Predictors of response to dipeptidyl peptidase‐4 inhibitors: evidence from randomized clinical trials

  2011cited by this paper
• Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin

  2011cited by this paper
• Association of increased plasma adipocyte fatty acid-binding protein with coronary artery disease in non-elderly men

  2011cited by this paper
• Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial.

  2010cited by this paper
• DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks

  2010cited by this paper
• Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus

  2010cited by this paper
• Interactive Hemodynamic Effects of Dipeptidyl Peptidase-IV Inhibition and Angiotensin-Converting Enzyme Inhibition in Humans

  2010cited by this paper
• Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.

  2010cited by this paper
• Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation.

  2010cited by this paper
• Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

  2009cited by this paper
• Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial

  2009cited by this paper
• Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study.

  2009cited by this paper
• Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.

  2009cited by this paper
• Effect of Initial Combination Therapy With Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, and Metformin on Glycemic Control in Patients With Type 2 Diabetes

  2008cited by this paper
• Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus.

  2008cited by this paper
• 10-year follow-up of intensive glucose control in type 2 diabetes.

  2008cited by this paper
• Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes.

  2008cited by this paper
• Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes

  2008cited by this paper
• Vildagliptin: a new oral treatment for type 2 diabetes mellitus

  2008cited by this paper
• Effects of Once-Weekly Dosing of a Long-Acting Release Formulation of Exenatide on Glucose Control and Body Weight in Subjects With Type 2 Diabetes

  2008cited by this paper
• Effect of Sitagliptin, a Dipeptidyl Peptidase‐4 Inhibitor, on Blood Pressure in Nondiabetic Patients With Mild to Moderate Hypertension

  2008cited by this paper
• Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial

  2007cited by this paper
• Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.

  2007cited by this paper
• The physiology of glucagon-like peptide 1.

  2007cited by this paper
• Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes

  2006cited by this paper
• Standards of Medical Care in Diabetes: Response to position statement of the American Diabetes Association

  2006cited by this paper
• Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.

  2005cited by this paper
• Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.

  2005cited by this paper
• Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.

  2004cited by this paper
• O R I G I N a L I N V E S T I G a T I O N Open Access

  year unknowncited by this paper
• CARDIO VASCULAR DIABETOLOGY ORIGINAL INVESTIGATION Open Access Cardiovascular safety of exenatide BID: an

  year unknowncited by this paper

• The Role of Insulin Resistance in Cardiorenal Metabolic Syndrome.

  2025cites this paper
• Metabolic-Associated Steatotic Liver Disease: From Molecular Mechanisms to Novel Therapies

  2025cites this paper
• Position of SGLT2i in prediabetes: A systematic review of literature

  2025cites this paper
• Therapeutic Efficacy of Scopoletin on Oxidative Stress and Cardiac Dysfunction in Streptozotocin-Induced Diabetic Rats.

  2025cites this paper
• Recent Advances in Perioperative Care of Patients using New Antihyperglycaemic Drugs and Devices Dedicated to Diabetes.

  2024cites this paper
• Comparison of protective effects of teneligliptin and luseogliflozin on pancreatic β-cell function: randomized, parallel-group, multicenter, open-label study (SECRETE-I study)

  2024cites this paper
• Novel Approaches for the Management of Type 2 Diabetes Mellitus: An Update.

  2023cites this paper
• In Search of Novel SGLT2 Inhibitors by High-throughput Virtual Screening.

  2023cites this paper
• Exploring SGLT-2 Inhibitors: Benefits beyond the Glucose-Lowering Effect—What Is New in 2023?

  2023influential citation
• Response to Comment on Lee et al. Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Retinal Vein Occlusion Among Patients With Type 2 Diabetes: A Propensity Score-Matched Cohort Study. Diabetes Care 2021; 44:2419-2426.

  2022cites this paper
• Reno Protective Effect of Sodium Glucose Cotransporter-2 Inhibitor (Dapagliflozin) in Type 2 Diabetic Patients

  2022cites this paper
• Knowledge and practice of community pharmacists towards SGLT2 inhibitors

  2022cites this paper
• Metformin-based single pill drug combinations for type 2 diabetes in primary care England: A time trend analysis.

  2022cites this paper
• Self-Induced Euglycemic Diabetic Ketoacidosis: When to Stop the Drip

  2022cites this paper
• Combatting chronic metabolic disorders and delaying aging by improving glucose-insulin metabolism and fat accumulation in nondiabetics

  2022cites this paper
• Approvals of type 2 diabetes drugs tested in cardiovascular outcome trials: A tripartite comparison

  2021cites this paper
• Effects of sodium‐glucose cotransporter type 2 inhibitors on cardiovascular, renal, and safety outcomes in patients with cardiovascular disease: a meta‐analysis of randomized controlled trials

  2021cites this paper
• Current status of Sodium-Glucose Co-Transporter Type 2 (SGLT2) inhibitors in treating diabetes mellitus

  2021cites this paper
• Challenges in Implementing Evidence Based Cross-Disciplinary Therapies: Are Cardiovascular Specialists Ready to Claim SGLT-2 Inhibitors and GLP-1 Analogs?

  2021cites this paper
• The Na/K-ATPase Signaling and SGLT2 Inhibitor-Mediated Cardiorenal Protection: A Crossed Road?

  2021cites this paper
• Sodium–Glucose Cotransporter 2 Inhibitors and Risk of Retinal Vein Occlusion Among Patients With Type 2 Diabetes: A Propensity Score–Matched Cohort Study

  2021cites this paper
• Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Concurrent Type 2 Diabetes Mellitus and Non-Alcoholic Steatohepatitis: A Review of the Evidence

  2021cites this paper
• New glucose-lowering drugs in patients with heart failure

  2021cites this paper
• Effect of SGLT2-Inhibitors on Epicardial Adipose Tissue: A Meta-Analysis

  2021cites this paper
• A practical review of diabetes mellitus type 2 treatment in primary care

  2021cites this paper
• Euglycemic Diabetic Ketoacidosis Caused by SGLT2 Inhibitors and a Ketogenic Diet: A Case Series and Review of Literature

  2020cites this paper
• Effect of sodium-glucose transport protein 2 inhibitors on serum uric acid: an outpatient based prospective interventional study

  2020cites this paper
• Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk

  2020cites this paper
• Effect of sodium-glucose co-transporter 2 inhibitors on lipid profile: a systematic review and meta-analysis of 48 randomized controlled trials.

  2020cites this paper
• SGLT 2 Inhibitors: Review of Systemic Effects and Safety

  2020cites this paper
• Perspective of SGLT2 Inhibition in Treatment of Conditions Connected to Neuronal Loss: Focus on Alzheimer’s Disease and Ischemia-Related Brain Injury

  2020cites this paper
• Adverse Effects of Glycemia-Lowering Medications in Type 2 Diabetes

  2019cites this paper
• Role of sodium-glucose co-transporter-2 inhibitors in the management of nonalcoholic fatty liver disease

  2019cites this paper
• Optimizing Glycemic Control of Diabetes Mellitus in Older Adults – A Tailored Approach

  2019cites this paper
• Emerging glucose-lowering therapies: a guide for cardiologists

  2019cites this paper
• Pharmacological Agents Utilized in Patients With Type-2 Diabetes: Beyond Lowering A1c.

  2018cites this paper
• Use of sodium–glucose cotransporter 2 inhibitors in older patients with type 2 diabetes mellitus

  2018cites this paper
• Liraglutide improves hepatic insulin resistance via the canonical Wnt signaling pathway.

  2018cites this paper
• Use of Canagliflozin in Combination With and Compared to Incretin-Based Therapies in Type 2 Diabetes

  2017cites this paper
• Garcinia kola aqueous suspension prevents cerebellar neurodegeneration in long-term diabetic rat - a type 1 diabetes mellitus model.

  2017cites this paper
• The Cardiovascular and Blood Pressure Effects and Safety of the SGLT2 Inhibitors

  2017cites this paper
• Relaxin-2 in Cardiometabolic Diseases: Mechanisms of Action and Future Perspectives

  2017cites this paper
• Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review

  2016cites this paper
• Cardiovascular effects of sodium–glucose cotransporter 2 inhibitors: multiple actions

  2016cites this paper
• Renoprotective effect of DPP-4 inhibitors against free fatty acid-bound albumin-induced renal proximal tubular cell injury.

  2016cites this paper
• Cardiovascular effects of anti-diabetes drugs

  2016cites this paper
• An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus

  2016cites this paper
• Diabetes, More on Merde, the Microbiome, and the Dung Beetle.

  2015cites this paper
• Emerging Diabetes Research: Prevention, Risk and Management.

  2015cites this paper
• Cardiovascular effects of dipeptidyl peptidase-4 inhibitors.

  2015cites this paper